(Repeats to add correct ticker symbol)
By Carl O'Donnell
Nov 1 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VAPI.UL is in talks to sell its Salix stomach business to Japanese pharmaceutical company Takeda Pharamceutical Co Ltd 4502.T , according to people familiar with the matter.
The deal could potentially raise as much as $10 billion for the indebted drugmaker, the people said, asking not to be identified because the discussions are private. There is no guarantee that the discussions will lead to a deal, they said.
Valeant is working with investment bank Morgan Stanley (NYSE:MS) on the sale, they added. News of the talks was first reported by the Wall Street Journal.